Related references
Note: Only part of the references are listed.The Role of Gene Body Cytosine Modifications in MGMT Expression and Sensitivity to Temozolomide
Erika L. Moen et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Walter Taal et al.
LANCET ONCOLOGY (2014)
EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma
Michael Weller et al.
LANCET ONCOLOGY (2014)
MGMT testing-the challenges for biomarker-based glioma treatment
Wolfgang Wick et al.
NATURE REVIEWS NEUROLOGY (2014)
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma
Andrew D. Norden et al.
NEURO-ONCOLOGY (2013)
Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation
Wolfgang Wick et al.
NEURO-ONCOLOGY (2013)
Predictive impact of MGMT promoter methylation in glioblastoma of the elderly
Guido Reifenberger et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Annika Malmstrom et al.
LANCET ONCOLOGY (2012)
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Wolfgang Wick et al.
LANCET ONCOLOGY (2012)
Extent and Patterns of MGMT Promoter Methylation in Glioblastoma- and Respective Glioblastoma-Derived Spheres
Davide Sciuscio et al.
CLINICAL CANCER RESEARCH (2011)
Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial
Jaime Gallego Perez-Larraya et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
Roger Stupp et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
James R. Perry et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Michael Weller et al.
NATURE REVIEWS NEUROLOGY (2010)
Temozolomide Concomitant and Adjuvant to Radiotherapy in Elderly Patients With Glioblastoma Correlation With MGMT Promoter Methylation Status
Alba A. Brandes et al.
CANCER (2009)
Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas
Sibille Everhard et al.
NEURO-ONCOLOGY (2009)
Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma
Ilse Vlassenbroeck et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2008)
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma
Antje Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide
ME Hegi et al.
CLINICAL CANCER RESEARCH (2004)
Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: A prospective randomized clinical trial
W Roa et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future
M Esteller
ONCOGENE (2002)
Current and future developments in the use of temozolomide for the treatment of brain tumours
R Stupp et al.
LANCET ONCOLOGY (2001)
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
M Esteller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Repair of O6-alkylguanine by alkyltransferases
AE Pegg
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2000)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
WKA Yung et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
